v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

RISK FACTORS AND PREVALENCE OF PERIPHERAL NEUROPATHY AMONG PATIENTS OF TYPE II DIABETES MELLITUS

AUTHORS:

Iqra Mazhar, Dr Syeda Fatima Murtaza, Maryam Waheed Khan

ABSTRACT:

Aim: A study was conducted to assess the prevalence and risk factors for diabetic neuropathy in DM2 patients, taking into account the increasing burden of type 2 (DM2) diabetes worldwide and associated microvascular and macrovascular complications. Place and Duration: In the Medicine Unit II of Jinnah Hospital Lahore for six months duration from October 2019 to March 2020. Methods: Patients aged 30 years and older who enrolled with DM2 were included in the study. Diabetic neuropathy symptoms (DNS) questionnaire was used to assess symptoms, and diabetic neuropathy (DNE) scores were used to assess clinical results. Results: A total of 273 patients were included. The average age was 57.8 ± 11.5. The distribution of men among women was 75% (202) and 25% (71), respectively. According to the DNS tool, 41.4% of patients were positive for the presence of neuropathy, and only 24.5% had neuropathy based on the DNE result. The percentage of men affected by neuropathy was higher than women. DNS results were positive in 43.1% of men and DNE only 27.2%. The duration of the disease was positively correlated with neuropathy. Neuropathy was more common in people with high systolic and diastolic blood pressure than DNS and DNE devices. Conclusion: The study showed a higher percentage of men affected by neuropathy. Therefore, a more detailed assessment should be made for older men with diabetes who have a longer duration of the disease. Lifestyle changes and careful testing should be considered as part of routine patient health education during follow-up visits. Key words: diabetic neuropathy test, symptomatic of diabetic neuropathy, peripheral neuropathy, prevalence, risk factors, type 2 diabetes

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.